logo

For the Inventor, By the Inventor

Seoul, South Korea

Good T Cells, Inc.


USPTO Granted Patents = 14


Forward Citations = 1

Loading Chart...
Loading Chart...

6 inventors (with patents filed for the assignee):

goldMedal Beom Seok Kim (8 out of 38 patents)

silverMedal Jung Ho Kim (8 out of 122 patents)

bronzeMedal Sang-Kyou Lee (6 out of 11 patents)

4.  Sung-Dong Park (3 out of 3 patents)

5.  Chin Hee Mun (1 out of 1 patent)

6.  Sang Won Lee (1 out of 90 patents)

7.  Ye Kyung Seong (1 patent)

8.  Jen Young Cho (1 patent)

9.  Sang Hwa Yang (1 patent)

10.  Jong Hyun Park (71 patents)

11.  Tae Yoon Park (0 patent)


14 patents:

1. 11999785 - Binding molecule specific for Lrig-1 protein and use thereof (2024-06-04),
2. 11969463 - Method for activating T cells for cancer treatment (2024-04-30),
3. 11932686 - Use of regulatory T cell-specific surface protein LRIG-1 (2024-03-19),
4. 11918634 - Method for activating T cells for cancer treatment (2024-03-05),
5. 11890364 - Composition for prevention or treatment of hair loss (2024-02-06),
6. 11820801 - Fusion protein, and pharmaceutical composition for preventing or treating cancer, containing same (2023-11-21),
7. 11655287 - Use of regulatory T cell-specific surface protein LRIG-1 (2023-05-23),
8. 11414467 - Fusion protein comprising transcription modulation domain of p65 and protein transduction domain, and uses thereof (2022-08-16),
9. 11365249 - Binding molecule specific for Lrig-1 protein and use thereof (2022-06-21),
10. 11345729 - Recombinant fusion protein of BAF57 and uses thereof (2022-05-31),
11. 11279756 - Binding molecule specific for LRIG-1 protein and use thereof (2022-03-22),
12. 11091538 - Use of regulatory T cell-specific surface protein LRIG-1 (2021-08-17),
13. 10544196 - Composition containing SMAD protein for treatment of autoimmune diseases, a fusion protein comprising SMAD protein, an expression vector and a method for preparing the same (2020-01-28),
14. 10494411 - Fusion protein comprising transcription modulation domain of p65 and protein transduction domain, and uses thereof (2019-12-03),
Company Overview
Good T Cells, Inc. is a biotechnology company based in Seoul, South Korea, specializing in the development of innovative immunotherapies. The organization focuses on harnessing the potential of T cells to create advanced treatments for various cancers and autoimmune diseases. By leveraging cutting-edge research in cellular therapy and immunology, Good T Cells aims to enhance patient outcomes and contribute to the evolving landscape of personalized medicine. Their commitment to scientific excellence positions them as a key player in the biopharmaceutical sector.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

14 Patents

#296 in Seoul

#826 in South Korea

#42,290 in the World

Seoul, KR
Seoul, South Korea

Good T Cells, Inc.

Forward Citations = 1

6 inventors:

goldMedal Beom Seok Kim (8 out of 38 patents)

silverMedal Jung Ho Kim (8 out of 122 patents)

bronzeMedal Sang-Kyou Lee (6 out of 11 patents)

4.  Sung-Dong Park (3 out of 3 patents)

5.  Chin Hee Mun (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Good T Cells, Inc.. Retrieved from https://idiyas.com/company/good-t-cells

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…